<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02618057</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH_P01</org_study_id>
    <nct_id>NCT02618057</nct_id>
  </id_info>
  <brief_title>Effects of Oral Steroid in Mycoplasma Pneumoniae Pneumonia</brief_title>
  <official_title>Effects of Oral Steroid in Mycoplasma Pneumoniae Pneumonia With Lobar Consolidation or Pleural Effusion in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mycoplasma pneumoniae is one of the most common causes of community-acquired pneumonia in
      children. The clinical course is typically self-limited and benign; however, rare cases of
      severe pneumonia can develop despite appropriate antibiotic therapy. The investigators aim to
      study the effects of prednisolone on severe M. pneumoniae pneumonia with lobar consolidation
      or pleural effusion in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mycoplasma pneumoniae is one of the most common causes of community-acquired pneumonia in
      children. The clinical course is typically self-limited and benign; however, rare cases of
      severe pneumonia can develop despite appropriate antibiotic therapy. The investigators aim to
      study the effects of prednisolone on severe M. pneumoniae pneumonia with lobar consolidation
      or pleural effusion in children. Participants will be randomly assigned (1:1 ratio) to
      receive either prednisone 1 mg/kg/d daily for 5 days or none. The primary endpoint was fever
      duration and analysed by intention to treat.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fever duration</measure>
    <time_frame>within the first 14 days after intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients improved in chest X-ray</measure>
    <time_frame>within the first 7 days after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with side effect of steroid</measure>
    <time_frame>within the first 14 days after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients improved in chest X-ray</measure>
    <time_frame>within the first 14 days after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Mycoplasma Pneumoniae Pneumonia</condition>
  <arm_group>
    <arm_group_label>Steroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prednisolone, 1.0 mg/kg/day, PO, for 5 days Levofloxacin, 10mg/kg/day, IV, for 5days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levofloxacin, 10mg/kg/day, IV, for 5days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>PO prednisolone, 1 mg/kg/day, for 5 days</description>
    <arm_group_label>Steroid</arm_group_label>
    <other_name>Solondo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>Levofloxacin, 10mg/kg/day, IV, for 5days</description>
    <arm_group_label>Steroid</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Evidence of Mycoplasma pneumoniae infection

          -  Lobar pneumonia or pneumoniae with pleural effusion

        Exclusion Criteria:

          -  Immunosuppresant host

          -  Chronic cardiovascular/pulmonary disease

          -  Hospital acquired infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eun Hwa Choi, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ki Wook Yun, M.D., Ph.D.</last_name>
    <phone>82-2-2072-4909</phone>
    <email>pedwilly@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Children's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki Wook Yun, Prof.</last_name>
      <phone>82-2-2072-4909</phone>
      <email>pedwilly@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2015</study_first_submitted>
  <study_first_submitted_qc>November 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2015</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pleuropneumonia</mesh_term>
    <mesh_term>Mycoplasma Infections</mesh_term>
    <mesh_term>Pneumonia, Mycoplasma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

